Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in China
Pfizer has paid $200 million to buy 9.9% of Hong Kong-listed cancer biotech CStone, beginning a strategic collaboration that will see the big US pharma gain rights to the company’s immunotherapy sugemalimab in China.
After buying the stake through a subsidiary, Pfizer has gained exclusive marketing rights to the PD-L1 checkpoint inhibitor in mainland China.
CStone will also receive up to $280 million in milestone payments, plus tiered royalties after Pfizer’s investment at $1.725 per share.
The companies think that sugemalimab could be a potential best-in-class PD-L1 antibody, which is being developed for common cancers including lung, gastric, and oesophageal cancers.
CStone and Pfizer will together select late-stage oncology assets for co-development in the Greater China market. These assets may come either from Pfizer’s pipeline or through joint in-licensing.
The companies may decide to pursue on a selected basis joint in-licensing arrangements for additional oncology assets for the Greater China market.
Trials of sugemalimab are ongoing: in addition to a phase 1 bridging study in the US the clinical programmes in China include one multi-arm phase Ib study for several tumour types, one phase II registrational study for lymphoma, and four phase III registrational studies, respectively, for stage III/IV non-small cell lung cancer, gastric cancer, and oesophageal cancer.
CStone will use the $200m to fund development activities and the strategic collaboration.
CStone has other collaborations too: it has rights for development and marketing of Blueprint Medicines’ targeted cancer drug Ayvakyt (avapritinib) in mainland China, Hong Kong, Macau, and Taiwan.
There are already three PD-L1 class drugs on the market, which differ from PD-1 inhibitors in that they directly block the ligand, or chemical signal, that allows cancer cells to hide from attacks from T cells.
Pfizer already markets a PD-L1, Bavencio (avelumab) in partnership with Germany’s Merck KGaA, with the other two approved drugs from the class being Roche’s Tecentriq (atezolizumab) and AstraZeneca’s Imfinzi (durvalumab).
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.